Approval · Notice of Compliance 25356 · 2021
FLOVENT DISKUS: Notice of Compliance 25356
Issued March 5, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25356
- Date
- March 5, 2021
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLOVENT DISKUS | Not yet assigned | — |
| FLOVENT HFA | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 100 MCG per BLD
- FLUTICASONE PROPIONATE 250 MCG per BLD
- FLUTICASONE PROPIONATE 500 MCG per BLD
- FLUTICASONE PROPIONATE 50 MCG per ACT
- FLUTICASONE PROPIONATE 125 MCG per ACT
- FLUTICASONE PROPIONATE 250 MCG per ACT